Prelude Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-331
| Closed | -$255K | – | 1523 |
|
|
2025
Q4 | $255K | Buy |
+331
| New | +$225K | 0.02% | 876 |
|
|
2025
Q3 | – | Sell |
-493
| Closed | -$259K | – | 1337 |
|
|
2025
Q2 | $259K | Buy |
493
+137
| +38% | +$76.5K | 0.03% | 680 |
|
|
2025
Q1 | $226K | Buy |
+356
| New | +$245K | 0.02% | 862 |
|
|
2024
Q4 | – | Sell |
-582
| Closed | -$612K | – | 1500 |
|
|
2024
Q3 | $612K | Buy |
+582
| New | +$648K | 0.04% | 541 |
|
|
2023
Q3 | – | Sell |
-692
| Closed | -$497K | – | 1316 |
|
|
2023
Q2 | $497K | Buy |
692
+201
| +41% | +$155K | 0.03% | 462 |
|
|
2023
Q1 | $403K | Buy |
+491
| New | +$370K | 0.02% | 533 |
|
|
2022
Q1 | – | Sell |
-1,145
| Closed | -$723K | – | 2155 |
|
|
2021
Q4 | $723K | Buy |
1,145
+323
| +39% | +$199K | 0.02% | 796 |
|
|
2021
Q3 | $497K | Sell |
822
-1,164
| -59% | -$723K | 0.01% | 900 |
|
|
2021
Q2 | $1.11M | Buy |
+1,986
| New | +$1.01M | 0.03% | 556 |
|
|
2021
Q1 | – | Sell |
-1,136
| Closed | -$549K | – | 1771 |
|
|
2020
Q4 | $549K | Buy |
1,136
+257
| +29% | +$139K | 0.01% | 696 |
|
|
2020
Q3 | $492K | Sell |
879
-390
| -31% | -$236K | 0.02% | 447 |
|
|
2020
Q2 | $791K | Buy |
1,269
+1,131
| +820% | +$642K | 0.04% | 369 |
|
|
2020
Q1 | $67K | Sell |
138
-2,229
| -94% | -$919K | ﹤0.01% | 691 |
|
|
2019
Q4 | $889K | Buy |
2,367
+2,320
| +4,936% | +$781K | 0.03% | 419 |
|
|
2019
Q3 | $13K | Sell |
47
-2,028
| -98% | -$600K | ﹤0.01% | 1457 |
|
|
2019
Q2 | $649K | Buy |
2,075
+1,543
| +290% | +$514K | 0.03% | 439 |
|
|
2019
Q1 | $218K | Sell |
532
-1,201
| -69% | -$495K | 0.01% | 689 |
|
|
2018
Q4 | $647K | Sell |
1,733
-428
| -20% | -$157K | 0.04% | 401 |
|
|
2018
Q3 | $873K | Buy |
2,161
+333
| +18% | +$127K | 0.05% | 397 |
|
|
2018
Q2 | $631K | Buy |
+1,828
| New | +$572K | 0.04% | 464 |
|
|
2017
Q4 | – | Sell |
-1,618
| Closed | -$723K | – | 1649 |
|
|
2017
Q3 | $723K | Buy |
1,618
+995
| +160% | +$473K | 0.07% | 301 |
|
|
2017
Q2 | $306K | Buy |
623
+114
| +22% | +$49.9K | 0.03% | 452 |
|
|
2017
Q1 | $197K | Buy |
+509
| New | +$189K | 0.02% | 567 |
|
|
2016
Q1 | – | Sell |
-963
| Closed | -$523K | – | 1482 |
|
|
2015
Q4 | $523K | Sell |
963
-498
| -34% | -$270K | 0.08% | 268 |
|
|
2015
Q3 | $680K | Sell |
1,461
-210
| -13% | -$113K | 0.1% | 233 |
|
|
2015
Q2 | $852K | Sell |
1,671
-60
| -3% | -$29.3K | 0.12% | 203 |
|
|
2015
Q1 | $782K | Buy |
1,731
+961
| +125% | +$407K | 0.11% | 230 |
|
|
2014
Q4 | $316K | Sell |
770
-273
| -26% | -$107K | 0.05% | 484 |
|
|
2014
Q3 | $376K | Buy |
1,043
+232
| +29% | +$77.8K | 0.05% | 478 |
|
|
2014
Q2 | $229K | Sell |
811
-1,059
| -57% | -$314K | 0.03% | 689 |
|
|
2014
Q1 | $562K | Sell |
1,870
-342
| -15% | -$105K | 0.08% | 351 |
|
|
2013
Q4 | $609K | Hold |
2,212
| – | – | 0.1% | 286 |
|
|
2013
Q3 | $692K | Sell |
2,212
-2,972
| -57% | -$782K | 0.11% | 220 |
|
|
2013
Q2 | $1.17M | Buy |
+5,184
| New | +$1.21M | 0.25% | 83 |
|
Other funds holding REGN
VCM
N
Prelude Capital Management's REGN Position: Q1 2026 in Review
Prelude Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 331 shares — an estimated $255K sold.
Prelude Capital Management first reported a position in REGN in Q2 2013 and held it in 34 quarters. The position peaked at $1.17M in Q2 2013. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Prelude Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Prelude Capital Management sold 331 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $255K.
- Prelude Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 34 quarters.
- Prelude Capital Management's Regeneron Pharmaceuticals position peaked at $1.17M in Q2 2013.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.